Search

Your search keyword '"Buchrieser, Julian"' showing total 147 results
Start Over Author "Buchrieser, Julian"
147 results on '"Buchrieser, Julian"'

1. Pregnancy complications and Interferon-induced transmembrane proteins (IFITM): balancing antiviral immunity and placental development

Author

Buchrieser, Julian and Schwartz, Olivier

Subjects
Placenta, Interferons, IFITMs, Syncytiotrophoblast, Cell–cell fusion, Biology (General), QH301-705.5
Abstract

Pregnancy complications occur frequently and are particularly prevalent during the first trimester. They are caused by a multitude of factors, including karyotypic, genetic or environmental conditions, congenital infections and inflammation. The molecular mechanisms leading to placental complications under inflammatory conditions remain unclear. In this review, we discuss how uncontrolled inflammation, triggered by viral infections or other diseases can lead to placental complications. We first highlight the importance of syncytins, ancestral retroviral genes co-opted by mammals including humans, millions of years ago for the process of placenta formation. We then focus on recent advances elucidating how interferon-induced transmembrane (IFITM) proteins, antiviral proteins rendering cells refractory to viral infections, interfere with placental development.

Published
2021
Full Text
View/download PDF

3. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion

Author

Planas, Delphine, Staropoli, Isabelle, Michel, Vincent, Lemoine, Frederic, Donati, Flora, Prot, Matthieu, Porrot, Francoise, Guivel-Benhassine, Florence, Jeyarajah, Banujaa, Brisebarre, Angela, Dehan, Océane, Avon, Léa, Bolland, William Henry, Hubert, Mathieu, Buchrieser, Julian, Vanhoucke, Thibault, Rosenbaum, Pierre, Veyer, David, Péré, Hélène, Lina, Bruno, Trouillet-Assant, Sophie, Hocqueloux, Laurent, Prazuck, Thierry, Simon-Loriere, Etienne, and Schwartz, Olivier

Published
2024
Full Text
View/download PDF

4. TMPRSS2 is a functional receptor for human coronavirus HKU1

Author

Saunders, Nell, Fernandez, Ignacio, Planchais, Cyril, Michel, Vincent, Rajah, Maaran Michael, Baquero Salazar, Eduard, Postal, Jeanne, Porrot, Francoise, Guivel-Benhassine, Florence, Blanc, Catherine, Chauveau-Le Friec, Gaëlle, Martin, Augustin, Grzelak, Ludivine, Oktavia, Rischa Maya, Meola, Annalisa, Ahouzi, Olivia, Hoover-Watson, Hunter, Prot, Matthieu, Delaune, Deborah, Cornelissen, Marion, Deijs, Martin, Meriaux, Véronique, Mouquet, Hugo, Simon-Lorière, Etienne, van der Hoek, Lia, Lafaye, Pierre, Rey, Felix, Buchrieser, Julian, and Schwartz, Olivier

Published
2023
Full Text
View/download PDF

7. Low CCR5 expression protects HIV-specific CD4+ T cells of elite controllers from viral entry

Author

Claireaux, Mathieu, Robinot, Rémy, Kervevan, Jérôme, Patgaonkar, Mandar, Staropoli, Isabelle, Brelot, Anne, Nouël, Alexandre, Gellenoncourt, Stacy, Tang, Xian, Héry, Mélanie, Volant, Stevenn, Perthame, Emeline, Avettand-Fenoël, Véronique, Buchrieser, Julian, Cokelaer, Thomas, Bouchier, Christiane, Ma, Laurence, Boufassa, Faroudy, Hendou, Samia, Libri, Valentina, Hasan, Milena, Zucman, David, de Truchis, Pierre, Schwartz, Olivier, Lambotte, Olivier, and Chakrabarti, Lisa A.

Published
2022
Full Text
View/download PDF

8. Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2

Author

Saunders, Nell, Planas, Delphine, Bolland, William H., Rodriguez, Christophe, Fourati, Slim, Buchrieser, Julian, Planchais, Cyril, Prot, Matthieu, Staropoli, Isabelle, Guivel-Benhassine, Florence, Porrot, Françoise, Veyer, David, Péré, Hélène, Robillard, Nicolas, Saliba, Madelina, Baidaliuk, Artem, Seve, Aymeric, Hocqueloux, Laurent, Prazuck, Thierry, Rey, Felix A., Mouquet, Hugo, Simon-Lorière, Etienne, Bruel, Timothée, Pawlotsky, Jean-Michel, and Schwartz, Olivier

Published
2022
Full Text
View/download PDF

9. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Author

Planas, Delphine, Saunders, Nell, Maes, Piet, Guivel-Benhassine, Florence, Planchais, Cyril, Buchrieser, Julian, Bolland, William-Henry, Porrot, Françoise, Staropoli, Isabelle, Lemoine, Frederic, Péré, Hélène, Veyer, David, Puech, Julien, Rodary, Julien, Baele, Guy, Dellicour, Simon, Raymenants, Joren, Gorissen, Sarah, Geenen, Caspar, Vanmechelen, Bert, Wawina-Bokalanga, Tony, Martí-Carreras, Joan, Cuypers, Lize, Sève, Aymeric, Hocqueloux, Laurent, Prazuck, Thierry, Rey, Félix A., Simon-Loriere, Etienne, Bruel, Timothée, Mouquet, Hugo, André, Emmanuel, and Schwartz, Olivier

Published
2022
Full Text
View/download PDF

11. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Author

Planas, Delphine, Bruel, Timothée, Grzelak, Ludivine, Guivel-Benhassine, Florence, Staropoli, Isabelle, Porrot, Françoise, Planchais, Cyril, Buchrieser, Julian, Rajah, Maaran Michael, Bishop, Elodie, Albert, Melanie, Donati, Flora, Prot, Matthieu, Behillil, Sylvie, Enouf, Vincent, Maquart, Marianne, and Smati-Lafarge, Mounira

Subjects
Viral antibodies -- Physiological aspects -- Genetic aspects, Immune response -- Genetic aspects, Antibodies -- Physiological aspects -- Genetic aspects, Biological sciences, Health
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.7 and B.1.351 variants were first identified in the United Kingdom and South Africa, respectively, and have since spread to many countries. These variants harboring diverse mutations in the gene encoding the spike protein raise important concerns about their immune evasion potential. Here, we isolated infectious B.1.1.7 and B.1.351 strains from acutely infected individuals. We examined sensitivity of the two variants to SARS-CoV-2 antibodies present in sera and nasal swabs from individuals infected with previously circulating strains or who were recently vaccinated, in comparison with a D614G reference virus. We utilized a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection. Sera from 58 convalescent individuals collected up to 9 months after symptoms, similarly neutralized B.1.1.7 and D614G. In contrast, after 9 months, convalescent sera had a mean sixfold reduction in neutralizing titers, and 40% of the samples lacked any activity against B.1.351. Sera from 19 individuals vaccinated twice with Pfizer Cominarty, longitudinally tested up to 6 weeks after vaccination, were similarly potent against B.1.1.7 but less efficacious against B.1.351, when compared to D614G. Neutralizing titers increased after the second vaccine dose, but remained 14-fold lower against B.1.351. In contrast, sera from convalescent or vaccinated individuals similarly bound the three spike proteins in a flow cytometry-based serological assay. Neutralizing antibodies were rarely detected in nasal swabs from vaccinees. Thus, faster-spreading SARS-CoV-2 variants acquired a partial resistance to neutralizing antibodies generated by natural infection or vaccination, which was most frequently detected in individuals with low antibody levels. Our results indicate that B1.351, but not B.1.1.7, may increase the risk of infection in immunized individuals. Sera from convalescent individuals with coronavirus disease 2019 and from individuals vaccinated with BNT162b2 have reduced ability to neutralize SARS-CoV-2 variants B1.1.7 and B.1.351, but antibody potency against the variants increases after two vaccine doses., Author(s): Delphine Planas [sup.1] [sup.2] [sup.3] , Timothée Bruel [sup.1] [sup.2] [sup.3] , Ludivine Grzelak [sup.1] [sup.2] [sup.3] [sup.4] , Florence Guivel-Benhassine [sup.1] [sup.2] [sup.3] , Isabelle Staropoli [sup.1] [sup.2] [...]

Published
2021
Full Text
View/download PDF

12. Understanding human mononuclear phagocyte ontogeny using human induced pluripotent stem cells (iPSCs)

Author

Buchrieser, Julian and James, William

Subjects
612.4, Hematopoiesis, Primitive hematopoiesis, Macrophage, MYB, SPI1, RUNX1
Abstract

Tissue-resident macrophages (MΦ) such as microglia, Kupffer and Langerhans cells derive from Myb-independent yolk sac (YS) progenitors generated before the emergence of hematopoietic stem cells (HSCs). Myb-independent YS-derived resident MΦ self-renew locally, independently of circulating adult monocytes and HSCs. In contrast, adult blood monocytes as well as infiltrating, gut and dermal MΦ derive from Myb-dependent HSCs and are less proliferative. These findings are derived from the mouse, using gene knock-outs and lineage tracing, but their applicability to human development has not been formally demonstrated. Here I use a human pluripotent stem cell (hPSC) differentiation model of hematopoiesis, capable of monocyte/MΦ production over prolonged periods of time, as a tool to investigate human mononuclear phagocyte ontogeny. Using a transcriptomic approach I showed that hiPSC-derived monocytes/MΦ (iPS-Mo/MΦ) produced early in differentiation (first weeks) are more proliferative and less immunologically mature than iPS-Mo/MΦ produced at a later time point. I therefore hypothesised either that iPS-Mo/MΦ only become fully mature after several weeks of differentiation or that there are two developmentally distinct waves of MΦ produced over time. By comparing the transcription profile of iPS-Mo/MΦs to that of primary adult blood monocytes and fetal microglia I then showed that early and late iPS-Mo/MΦs were transcriptionally closer to fetal microglia than to adult blood monocytes. To further investigate if iPS-Mo/MΦs are indeed of the same developmental origin as MYB-independent MΦ such as microglia, I used a CRISPR-Cas9 knock-out strategy to show for the first time, that human iPS-Mo/MΦs develop in a MYB-independent, RUNX1 and SPI1 (PU.1)-dependent fashion. This result makes human iPS-Mo/MΦs developmentally related to, and a good model for, MYB-independent tissue-resident \Macros such as alveolar and kidney MΦs, microglia, Kupffer and Langerhans cells. Interestingly, while MYB was not required for the generation of iPS-Mo/MΦs, its knock-out resulted in an increase in iPS-Mo/MΦ production. To investigate this increase I developed two methods for quantifying the differentiation bottleneck occurring during hiPSC differentiation to iPS-Mo/MΦs. Those techniques highlighted a potential increase in progenitor cell generation in MYB KO cells and thus lay foundation to improve our technical understanding of EB differentiation and will enable enhanced manipulation of the EB model.

Published
2016

13. Structural basis of TMPRSS2 zymogen activation and recognition by the HKU1 seasonal coronavirus

Author

Fernández, Ignacio, primary, Saunders, Nell, additional, Duquerroy, Stéphane, additional, Bolland, William H., additional, Arbabian, Atousa, additional, Salazar, Eduard Baquero, additional, Blanc, Catherine, additional, Lafaye, Pierre, additional, Haouz, Ahmed, additional, Buchrieser, Julian, additional, Schwartz, Olivier, additional, and Rey, Félix A., additional

Published
2024
Full Text
View/download PDF

14. High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1

Author

Bolland, William, primary, Michel, Vincent, additional, Planas, Delphine, additional, Hubert, Mathieu, additional, Staropoli, Isabelle, additional, Guivel-Benhassine, Florence, additional, Porrot, Françoise, additional, N'Debi, Mélissa, additional, Rodriguez, Christophe, additional, Fourati, Slim, additional, Prot, Matthieu, additional, Planchais, Cyril, additional, Hocqueloux, Laurent, additional, Simon-Lorière, Etienne, additional, Mouquet, Hugo, additional, Prazuck, Thierry, additional, Pawlotsky, Jean-Michel, additional, Bruel, Timothée, additional, Schwartz, Olivier, additional, and Buchrieser, Julian, additional

Published
2023
Full Text
View/download PDF

17. 9:10-9:30 IFN, TORCH, IFITM & pregnancy

Author

Degrelle, Séverine A., primary, Dupressoir, Anne, additional, Buchrieser, Julian, additional, Porrot, Françoise, additional, Schwartz, Olivier, additional, and Fournier, Thierry, additional

Published
2023
Full Text
View/download PDF

19. Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies

Author

Bruel, Timothée, primary, Stéfic, Karl, additional, Nguyen, Yann, additional, Toniutti, Donatella, additional, Staropoli, Isabelle, additional, Porrot, Françoise, additional, Guivel-Benhassine, Florence, additional, Bolland, William-Henry, additional, Planas, Delphine, additional, Hadjadj, Jérôme, additional, Handala, Lynda, additional, Planchais, Cyril, additional, Prot, Matthieu, additional, Simon-Lorière, Etienne, additional, André, Emmanuel, additional, Baele, Guy, additional, Cuypers, Lize, additional, Mouthon, Luc, additional, Mouquet, Hugo, additional, Buchrieser, Julian, additional, Sève, Aymeric, additional, Prazuck, Thierry, additional, Maes, Piet, additional, Terrier, Benjamin, additional, Hocqueloux, Laurent, additional, and Schwartz, Olivier, additional

Published
2022
Full Text
View/download PDF

20. The Spike-Stabilizing D614G Mutation Interacts with S1/S2 Cleavage Site Mutations To Promote the Infectious Potential of SARS-CoV-2 Variants

Author

Gellenoncourt, Stacy, primary, Saunders, Nell, additional, Robinot, Rémy, additional, Auguste, Lucas, additional, Rajah, Maaran Michael, additional, Kervevan, Jérôme, additional, Jeger-Madiot, Raphaël, additional, Staropoli, Isabelle, additional, Planchais, Cyril, additional, Mouquet, Hugo, additional, Buchrieser, Julian, additional, Schwartz, Olivier, additional, and Chakrabarti, Lisa A., additional

Published
2022
Full Text
View/download PDF

22. Species-Specific Molecular Barriers to SARS-CoV-2 Replication in Bat Cells

Author

Aicher, Sophie-Marie, primary, Streicher, Felix, additional, Chazal, Maxime, additional, Planas, Delphine, additional, Luo, Dongsheng, additional, Buchrieser, Julian, additional, Nemcova, Monika, additional, Seidlova, Veronika, additional, Zukal, Jan, additional, Serra-Cobo, Jordi, additional, Pontier, Dominique, additional, Pain, Bertrand, additional, Zimmer, Gert, additional, Schwartz, Olivier, additional, Roingeard, Philippe, additional, Pikula, Jiri, additional, Dacheux, Laurent, additional, and Jouvenet, Nolwenn, additional

Published
2022
Full Text
View/download PDF

24. Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2

Author

Saunders, Nell, primary, Planas, Delphine, additional, Bolland, William, additional, Rodriguez, Christophe, additional, Fourati, Slim, additional, Buchrieser, Julian, additional, Planchais, Cyril, additional, Prot, Matthieu, additional, Staropoli, Isabelle, additional, Guivel-Benhassine, Florence, additional, Porrot, Françoise, additional, Veyer, David, additional, Péré, Hélène, additional, Robillard, Nicolas, additional, Saliba, Madelina, additional, Baidaliuk, Artem, additional, Seve, Aymeric, additional, Hocqueloux, Laurent, additional, Prazuck, Thierry, additional, Mouquet, Hugo, additional, Simon-Lorière, Etienne, additional, Bruel, Timothée, additional, Pawlotsky, Jean-Michel, additional, and Schwartz, Olivier, additional

Published
2022
Full Text
View/download PDF

25. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Author

Planas, Delphine, primary, Saunders, Nell, additional, Maes, Piet, additional, Guivel-Benhassine, Florence, additional, Planchais, Cyril, additional, Buchrieser, Julian, additional, Bolland, William-Henry, additional, Porrot, Françoise, additional, Staropoli, Isabelle, additional, Lemoine, Frederic, additional, Péré, Hélène, additional, Veyer, David, additional, Puech, Julien, additional, Rodary, Julien, additional, Baele, Guy, additional, Dellicour, Simon, additional, Raymenants, Joren, additional, Gorissen, Sarah, additional, Geenen, Caspar, additional, Vanmechelen, Bert, additional, Wawina-Bokalanga, Tony, additional, Martí-Carreras, Joan, additional, Cuypers, Lize, additional, Sève, Aymeric, additional, Hocqueloux, Laurent, additional, Prazuck, Thierry, additional, Rey, Félix A., additional, Simon-Loriere, Etienne, additional, Bruel, Timothée, additional, Mouquet, Hugo, additional, André, Emmanuel, additional, and Schwartz, Olivier, additional

Published
2021
Full Text
View/download PDF

26. Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization

Author

Planas, Delphine, primary, Saunders, Nell, additional, Maes, Piet, additional, Guivel-Benhassine, Florence, additional, Planchais, Cyril, additional, Buchrieser, Julian, additional, Bolland, William-Henry, additional, Porrot, Françoise, additional, Staropoli, Isabelle, additional, Lemoine, Frederic, additional, Péré, Hélène, additional, Veyer, David, additional, Puech, Julien, additional, Rodary, Julien, additional, Baela, Guy, additional, Dellicour, Simon, additional, Raymenants, Joren, additional, Gorissen, Sarah, additional, Geenen, Caspar, additional, Vanmechelen, Bert, additional, Wawina-Bokalanga, Tony, additional, Martí-Carrerasi, Joan, additional, Cuypers, Lize, additional, Sève, Aymeric, additional, Hocqueloux, Laurent, additional, Prazuck, Thierry, additional, Rey, Félix, additional, Simon-Lorrière, Etienne, additional, Bruel, Timothée, additional, Mouquet, Hugo, additional, André, Emmanuel, additional, and Schwartz, Olivier, additional

Published
2021
Full Text
View/download PDF

27. SARS‐CoV‐2 Alpha, Beta, and Delta variants display enhanced Spike‐mediated syncytia formation

Author

Rajah, Maaran Michael, primary, Hubert, Mathieu, additional, Bishop, Elodie, additional, Saunders, Nell, additional, Robinot, Remy, additional, Grzelak, Ludivine, additional, Planas, Delphine, additional, Dufloo, Jérémy, additional, Gellenoncourt, Stacy, additional, Bongers, Alice, additional, Zivaljic, Marija, additional, Planchais, Cyril, additional, Guivel‐Benhassine, Florence, additional, Porrot, Françoise, additional, Mouquet, Hugo, additional, Chakrabarti, Lisa A, additional, Buchrieser, Julian, additional, and Schwartz, Olivier, additional

Published
2021
Full Text
View/download PDF

29. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Author

Planas, Delphine, Saunders, Nell, Maes, Piet, Guivel-Benhassine, Florence, Planchais, Cyril, Buchrieser, Julian, Bolland, William Henry, Porrot, Françoise, Staropoli, Isabelle, Lemoine, Frédéric, Péré, Hélène, Veyer, David, Puech, Julien, Rodary, Julien, Baele, Guy, Dellicour, Simon, Raymenants, Joren, Gorissen, Sarah, Geenen, Caspar, Vanmechelen, Bert, Wawina-Bokalanga, Tony, Martí-Carreras, Joan, Cuypers, Lize, Sève, Aymeric, Hocqueloux, Laurent, Prazuck, Thierry, Rey, Felix, Simon-Loriere, Etienne, Bruel, Timothée, Mouquet, Hugo, André, Emmanuel, Schwartz, Olivier, Planas, Delphine, Saunders, Nell, Maes, Piet, Guivel-Benhassine, Florence, Planchais, Cyril, Buchrieser, Julian, Bolland, William Henry, Porrot, Françoise, Staropoli, Isabelle, Lemoine, Frédéric, Péré, Hélène, Veyer, David, Puech, Julien, Rodary, Julien, Baele, Guy, Dellicour, Simon, Raymenants, Joren, Gorissen, Sarah, Geenen, Caspar, Vanmechelen, Bert, Wawina-Bokalanga, Tony, Martí-Carreras, Joan, Cuypers, Lize, Sève, Aymeric, Hocqueloux, Laurent, Prazuck, Thierry, Rey, Felix, Simon-Loriere, Etienne, Bruel, Timothée, Mouquet, Hugo, André, Emmanuel, and Schwartz, Olivier

Abstract

The SARS-CoV-2 Omicron variant was first identified in November 2021 in Botswana and South Africa1–3. It has since then spread to many countries and is expected to rapidly become dominant worldwide. The lineage is characterized by the presence of about 32 mutations in the spike, located mostly in the N-terminal domain (NTD) and the receptor binding domain (RBD), which may enhance viral fitness and allow antibody evasion. Here, we isolated an infectious Omicron virus in Belgium, from a traveller returning from Egypt. We examined its sensitivity to 9 monoclonal antibodies (mAbs) clinically approved or in development4, and to antibodies present in 115 sera from COVID-19 vaccine recipients or convalescent individuals. Omicron was totally or partially resistant to neutralization by all mAbs tested. Sera from Pfizer or AstraZeneca vaccine recipients, sampled 5 months after complete vaccination, barely inhibited Omicron. Sera from COVID-19 convalescent patients collected 6 or 12 months post symptoms displayed low or no neutralizing activity against Omicron. Administration of a booster Pfizer dose as well as vaccination of previously infected individuals generated an anti-Omicron neutralizing response, with titers 6 to 23 fold lower against Omicron than against Delta. Thus, Omicron escapes most therapeutic monoclonal antibodies and to a large extent vaccine-elicited antibodies. Omicron remains however neutralized by antibodies generated by a booster vaccine dose., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2021

30. Species-specific molecular barriers to SARS-CoV-2 replication in bat cells

Author

Aicher, Sophie-Marie, primary, Streicher, Felix, additional, Chazal, Maxime, additional, Planas, Delphine, additional, Luo, Dongsheng, additional, Buchrieser, Julian, additional, Nemcova, Monika, additional, Seidlova, Veronika, additional, Zukal, Jan, additional, Serra-Cobo, Jordi, additional, Pontier, Dominique, additional, Schwartz, Olivier, additional, Pikula, Jiri, additional, Dacheux, Laurent, additional, and Jouvenet, Nolwenn, additional

Published
2021
Full Text
View/download PDF

31. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Author

Planas, Delphine, primary, Bruel, Timothée, additional, Grzelak, Ludivine, additional, Guivel-Benhassine, Florence, additional, Staropoli, Isabelle, additional, Porrot, Françoise, additional, Planchais, Cyril, additional, Buchrieser, Julian, additional, Rajah, Maaran Michael, additional, Bishop, Elodie, additional, Albert, Mélanie, additional, Donati, Flora, additional, Behillil, Sylvie, additional, Enouf, Vincent, additional, Maquart, Marianne, additional, Gonzalez, Maria, additional, De Sèze, Jérôme, additional, Péré, Hélène, additional, Veyer, David, additional, Sève, Aymeric, additional, Simon-Lorière, Etienne, additional, Fafi-Kremer, Samira, additional, Stefic, Karl, additional, Mouquet, Hugo, additional, Hocqueloux, Laurent, additional, van der Werf, Sylvie, additional, Prazuck, Thierry, additional, and Schwartz, Olivier, additional

Published
2021
Full Text
View/download PDF

32. Syncytia formation by SARS‐CoV‐2‐infected cells

Author

Buchrieser, Julian, primary, Dufloo, Jérémy, additional, Hubert, Mathieu, additional, Monel, Blandine, additional, Planas, Delphine, additional, Rajah, Maaran Michael, additional, Planchais, Cyril, additional, Porrot, Françoise, additional, Guivel‐Benhassine, Florence, additional, Van der Werf, Sylvie, additional, Casartelli, Nicoletta, additional, Mouquet, Hugo, additional, Bruel, Timothée, additional, and Schwartz, Olivier, additional

Published
2021
Full Text
View/download PDF

34. Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies

Author

Dufloo, Jérémy, primary, Grzelak, Ludivine, additional, Staropoli, Isabelle, additional, Madec, Yoann, additional, Tondeur, Laura, additional, Anna, François, additional, Pelleau, Stéphane, additional, Wiedemann, Aurélie, additional, Planchais, Cyril, additional, Buchrieser, Julian, additional, Robinot, Rémy, additional, Ungeheuer, Marie-Noëlle, additional, Mouquet, Hugo, additional, Charneau, Pierre, additional, White, Michael, additional, Lévy, Yves, additional, Hoen, Bruno, additional, Fontanet, Arnaud, additional, Schwartz, Olivier, additional, and Bruel, Timothée, additional

Published
2020
Full Text
View/download PDF

35. Syncytia formation by SARS‐CoV‐2‐infected cells

Author

Buchrieser, Julian, primary, Dufloo, Jérémy, additional, Hubert, Mathieu, additional, Monel, Blandine, additional, Planas, Delphine, additional, Rajah, Maaran Michael, additional, Planchais, Cyril, additional, Porrot, Françoise, additional, Guivel‐Benhassine, Florence, additional, Van der Werf, Sylvie, additional, Casartelli, Nicoletta, additional, Mouquet, Hugo, additional, Bruel, Timothée, additional, and Schwartz, Olivier, additional

Published
2020
Full Text
View/download PDF

36. A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations

Author

Grzelak, Ludivine, primary, Temmam, Sarah, additional, Planchais, Cyril, additional, Demeret, Caroline, additional, Tondeur, Laura, additional, Huon, Christèle, additional, Guivel-Benhassine, Florence, additional, Staropoli, Isabelle, additional, Chazal, Maxime, additional, Dufloo, Jeremy, additional, Planas, Delphine, additional, Buchrieser, Julian, additional, Rajah, Maaran Michael, additional, Robinot, Remy, additional, Porrot, Françoise, additional, Albert, Mélanie, additional, Chen, Kuang-Yu, additional, Crescenzo-Chaigne, Bernadette, additional, Donati, Flora, additional, Anna, François, additional, Souque, Philippe, additional, Gransagne, Marion, additional, Bellalou, Jacques, additional, Nowakowski, Mireille, additional, Backovic, Marija, additional, Bouadma, Lila, additional, Le Fevre, Lucie, additional, Le Hingrat, Quentin, additional, Descamps, Diane, additional, Pourbaix, Annabelle, additional, Laouénan, Cédric, additional, Ghosn, Jade, additional, Yazdanpanah, Yazdan, additional, Besombes, Camille, additional, Jolly, Nathalie, additional, Pellerin-Fernandes, Sandrine, additional, Cheny, Olivia, additional, Ungeheuer, Marie-Noëlle, additional, Mellon, Guillaume, additional, Morel, Pascal, additional, Rolland, Simon, additional, Rey, Felix A., additional, Behillil, Sylvie, additional, Enouf, Vincent, additional, Lemaitre, Audrey, additional, Créach, Marie-Aude, additional, Petres, Stephane, additional, Escriou, Nicolas, additional, Charneau, Pierre, additional, Fontanet, Arnaud, additional, Hoen, Bruno, additional, Bruel, Timothée, additional, Eloit, Marc, additional, Mouquet, Hugo, additional, Schwartz, Olivier, additional, and van der Werf, Sylvie, additional

Published
2020
Full Text
View/download PDF

37. SUMOylation of SAMHD1 at Lysine 595 is required for HIV-1 restriction in non-cycling cells

Author

Martinat, Charlotte, primary, Cormier, Arthur, additional, Tobaly-Tapiero, Joёlle, additional, Palmic, Noé, additional, Casartelli, Nicoletta, additional, Coggins, Si’Ana A., additional, Buchrieser, Julian, additional, Persaud, Mirjana, additional, Diaz-Griffero, Felipe, additional, Espert, Lucile, additional, Bossis, Guillaume, additional, Lesage, Pascale, additional, Schwartz, Olivier, additional, Kim, Baek, additional, Margottin-Goguet, Florence, additional, Saïb, Ali, additional, and Zamborlini, Alessia, additional

Published
2020
Full Text
View/download PDF

38. SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors

Author

Grzelak, Ludivine, primary, Temmam, Sarah, additional, Planchais, Cyril, additional, Demeret, Caroline, additional, Huon, Christèle, additional, Guivel-Benhassine, Florence, additional, Staropoli, Isabelle, additional, Chazal, Maxime, additional, Dufloo, Jeremy, additional, Planas, Delphine, additional, Buchrieser, Julian, additional, Rajah, Maaran Michael, additional, Robinot, Remy, additional, Porrot, Françoise, additional, Albert, Mélanie, additional, Chen, Kuang-Yu, additional, Crescenzo, Bernadette, additional, Donati, Flora, additional, Anna, François, additional, Souque, Philippe, additional, Gransagne, Marion, additional, Bellalou, Jacques, additional, Nowakowski, Mireille, additional, Backovic, Marija, additional, Bouadma, Lila, additional, Fevre, Lucie Le, additional, Hingrat, Quentin Le, additional, Descamps, Diane, additional, Pourbaix, Annabelle, additional, Yazdanpanah, Yazdan, additional, Tondeur, Laura, additional, Besombes, Camille, additional, Ungeheuer, Marie-Noëlle, additional, Mellon, Guillaume, additional, Morel, Pascal, additional, Rolland, Simon, additional, Rey, Felix, additional, Behillil, Sylvie, additional, Enouf, Vincent, additional, Lemaitre, Audrey, additional, Créach, Marie-Aude, additional, Petres, Stephane, additional, Escriou, Nicolas, additional, Charneau, Pierre, additional, Fontanet, Arnaud, additional, Hoen, Bruno, additional, Bruel, Timothée, additional, Eloit, Marc, additional, Mouquet, Hugo, additional, Schwartz, Olivier, additional, and van der Werf, Sylvie, additional

Published
2020
Full Text
View/download PDF

39. Anti‐ HIV ‐1 antibodies trigger non‐lytic complement deposition on infected cells

Author

Dufloo, Jérémy, primary, Guivel‐Benhassine, Florence, additional, Buchrieser, Julian, additional, Lorin, Valérie, additional, Grzelak, Ludivine, additional, Dupouy, Emilie, additional, Mestrallet, Guillaume, additional, Bourdic, Katia, additional, Lambotte, Olivier, additional, Mouquet, Hugo, additional, Bruel, Timothée, additional, and Schwartz, Olivier, additional

Published
2019
Full Text
View/download PDF

40. Atlastin Endoplasmic Reticulum-Shaping Proteins Facilitate Zika Virus Replication

Author

Monel, Blandine, primary, Rajah, Maaran Michael, additional, Hafirassou, Mohamed Lamine, additional, Sid Ahmed, Samy, additional, Burlaud-Gaillard, Julien, additional, Zhu, Peng-Peng, additional, Nevers, Quentin, additional, Buchrieser, Julian, additional, Porrot, Françoise, additional, Meunier, Cécile, additional, Amraoui, Sonia, additional, Chazal, Maxime, additional, Salles, Audrey, additional, Jouvenet, Nolwenn, additional, Roingeard, Philippe, additional, Blackstone, Craig, additional, Amara, Ali, additional, and Schwartz, Olivier, additional

Published
2019
Full Text
View/download PDF

42. The Atlastin ER-shaping proteins facilitate Zika virus replication

Author

Monel, Blandine, Rajah, Maaran Michael, Hafirassou, Mohamed-Lamine, Sid-Ahmed, Samy, Burlaud-Gaillard, Julien, Zhu, Peng-Peng, Nevers, Quentin, Buchrieser, Julian, Porrot, Françoise, Meunier, Cécile, Amraoui, Sonia, Chazal, Maxime, Salles, Audrey, Jouvenet, Nolwenn, Roingeard, Philippe, Blackstone, Craig, Amara, Ali, schwartz, olivier, Virus et Immunité - Virus and immunity, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Ecole doctorale Bio Sorbonne Paris Cité (BioSPC) (ED 157), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5), Génomes, biologie cellulaire et thérapeutiques (GenCellDi (UMR_S_944)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Collège de France (CdF (institution))-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Plateforme IBISA de Microscopie Electronique [CHRU de Tours] (UNIV Tours), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Université de Tours (UT), Cell Biology Section, Neurogenetics Branch [Bethesda], National Institute of Neurological Disorders and Stroke [Bethesda] (NINDS), National Institutes of Health [Bethesda] (NIH)-National Institutes of Health [Bethesda] (NIH), Génomique virale et vaccination, Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris], BioImagerie Photonique – Photonic BioImaging (UTechS PBI), Institut Pasteur [Paris], Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)-Université de Tours, Virus et Immunité - Virus and immunity (CNRS-UMR3569), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Collège de France (CdF (institution))-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris] (IP), Virus et Immunité, Biologie cellulaire des infections virales, Collège de France (CdF)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Collège de France (CdF)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Tours-Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Technologie et Service BioImagerie Photonique – Photonic BioImaging (UTechS PBI), Centre de Ressources et de Recherche Technologique - Center for Technological Resources and Research (C2RT), and Institut Pasteur [Paris]-Institut Pasteur [Paris]

Subjects
[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology
Abstract

International audience; The endoplasmic reticulum (ER) is the site for Zika virus (ZIKV) replication and is central to the cytopathic effects observed in infected cells. ZIKV induces the formation of ER-derived large cytoplasmic vacuoles followed by “implosive” cell death. Little is known about the nature of the ER factors that regulate flavivirus replication. Atlastins (ATL1, -2, and -3) are dynamin-related GTPases that control the structure and the dynamics of the ER membrane. We show here that ZIKV replication is significantly decreased in the absence of ATL proteins. The appearance of infected cells is delayed, the levels of intracellular viral proteins and released virus are reduced, and the cytopathic effects are strongly impaired. We further show that ATL3 is recruited to viral replication sites and interacts with the nonstructural viral proteins NS2A and NS2B3. Thus, proteins that shape and maintain the ER tubular network ensure efficient ZIKV replication.IMPORTANCE Zika virus (ZIKV) is an emerging virus associated with Guillain-Barré syndrome, and fetal microcephaly as well as other neurological complications. There is no vaccine or specific antiviral treatment against ZIKV. We found that endoplasmic reticulum (ER)-shaping atlastin proteins (ATL1, -2, and -3), which induce ER membrane fusion, facilitate ZIKV replication. We show that ATL3 is recruited to the viral replication site and colocalize with the viral proteins NS2A and NS2B3. The results provide insights into host factors used by ZIKV to enhance its replication.

Published
2019

43. IFITM proteins inhibit placental syncytiotrophoblast formation and promote fetal demise

Author

Buchrieser, Julian, primary, Degrelle, Séverine A., additional, Couderc, Thérèse, additional, Nevers, Quentin, additional, Disson, Olivier, additional, Manet, Caroline, additional, Donahue, Daniel A., additional, Porrot, Françoise, additional, Hillion, Kenzo-Hugo, additional, Perthame, Emeline, additional, Arroyo, Marlene V., additional, Souquere, Sylvie, additional, Ruigrok, Katinka, additional, Dupressoir, Anne, additional, Heidmann, Thierry, additional, Montagutelli, Xavier, additional, Fournier, Thierry, additional, Lecuit, Marc, additional, and Schwartz, Olivier, additional

Published
2019
Full Text
View/download PDF

44. RIPK1 is a critical modulator of both tonic and TLR-responsive inflammatory and cell death pathways in human macrophage differentiation

Author

Universidad de Sevilla. Departamento de Bioquímica y Biología Molecular, Ministerio de Economía y Competitividad (MINECO). España, European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER), Buchrieser, Julian, Oliva Martín, María José, Moore, Michael D., Long, Joshua C. D., Cowley, Sally A., Pérez Simón, José Antonio, Venero Recio, José Luis, Universidad de Sevilla. Departamento de Bioquímica y Biología Molecular, Ministerio de Economía y Competitividad (MINECO). España, European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER), Buchrieser, Julian, Oliva Martín, María José, Moore, Michael D., Long, Joshua C. D., Cowley, Sally A., Pérez Simón, José Antonio, and Venero Recio, José Luis

Abstract

In this study, we took advantage of human-induced pluripotent stem cells (hiPSC) and CRISPR/Cas9 technology to investigate the potential roles of RIPK1 in regulating hematopoiesis and macrophage differentiation, proinflammatory activation, and cell death pathways. Knock-out of RIPK1 in hiPSCs demonstrated that this protein is not required for erythro-myeloid differentiation. Using a well-established macrophage differentiation protocol, knock-out of RIPK1 did not block the differentiation of iPSC-derived macrophages, which displayed a similar phenotype to WT hiPSC-derived macrophages. However, knock-out of RIPK1 leads to a TNFα-dependent apoptotic death of differentiated hiPSC-derived macrophages (iPS-MΦ) and progressive loss of iPS-MΦ production irrespective of external pro-inflammatory stimuli. Live video analysis demonstrated that TLR3/4 activation of RIPK1 KO hiPSC-derived macrophages triggered TRIF and RIPK3-dependent necroptosis irrespective of caspase-8 activation. In contrast, TLR3/4 activation of WT macrophages-induced necroptosis only when caspases were inhibited, confirming the modulating effect of RIPK1 on RIPK3-mediated necroptosis through the FADD, Caspase-8 pathway. Activation of these inflammatory pathways required RIPK3 kinase activity while RIPK1 was dispensable. However, loss of RIPK1 sensitizes macrophages to activate RIPK3 in response to inflammatory stimuli, thereby exacerbating a potentially pathological inflammatory response. Taken together, these results reveal that RIPK1 has an important role in regulating the potent inflammatory pathways in authentic human macrophages that are poised to respond to external stimuli. Consequently, RIPK1 activity might be a valid target in the development of novel therapies for chronic inflammatory diseases.

Published
2018

45. Anti‐HIV‐1 antibodies trigger non‐lytic complement deposition on infected cells.

Author

Dufloo, Jérémy, Guivel‐Benhassine, Florence, Buchrieser, Julian, Lorin, Valérie, Grzelak, Ludivine, Dupouy, Emilie, Mestrallet, Guillaume, Bourdic, Katia, Lambotte, Olivier, Mouquet, Hugo, Bruel, Timothée, and Schwartz, Olivier

Abstract

The effect of anti‐HIV‐1 antibodies on complement activation at the surface of infected cells remains partly understood. Here, we show that a subset of anti‐Envelope (Env) broadly neutralizing antibodies (bNAbs), targeting the CD4 binding site and the V3 loop, triggers C3 deposition and complement‐dependent cytotoxicity (CDC) on Raji cells engineered to express high surface levels of HIV‐1 Env. Primary CD4 T cells infected with laboratory‐adapted or primary HIV‐1 strains and treated with bNAbs are susceptible to C3 deposition but not to rapid CDC. The cellular protein CD59 and viral proteins Vpu and Nef protect infected cells from CDC mediated by bNAbs or by polyclonal IgGs from HIV‐positive individuals. However, complement deposition accelerates the disappearance of infected cells within a few days of culture. Altogether, our results uncover the contribution of complement to the antiviral activity of anti‐HIV‐1 bNAbs. Synopsis: Anti‐HIV‐1 antibodies trigger complement deposition at the surface of infected cells. Some viral and cellular components independently limit complement activation after infection, preventing rapid cell lysis, although coated cells disappear faster than non‐coated cells. Some anti‐HIV‐1 bNAbs and polyclonal antibodies trigger complement deposition on infected cells.Infected primary CD4 T cells resist complement lysis by bNAbs.Vpu, Nef and CD59 cooperate to limit complement activation by antibodies. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

46. A Highly Efficient Human Pluripotent Stem Cell Microglia Model Displays a Neuronal-Co-culture-Specific Expression Profile and Inflammatory Response

Author

Haenseler, Walther; https://orcid.org/0000-0003-4868-3704, Sansom, Stephen N, Buchrieser, Julian, Newey, Sarah E, Moore, Craig S, Nicholls, Francesca J, Chintawar, Satyan, Schnell, Christian, Antel, Jack P, Allen, Nicholas D, Cader, M Zameel, Wade-Martins, Richard, James, William S, Cowley, Sally A, Haenseler, Walther; https://orcid.org/0000-0003-4868-3704, Sansom, Stephen N, Buchrieser, Julian, Newey, Sarah E, Moore, Craig S, Nicholls, Francesca J, Chintawar, Satyan, Schnell, Christian, Antel, Jack P, Allen, Nicholas D, Cader, M Zameel, Wade-Martins, Richard, James, William S, and Cowley, Sally A

Abstract

Microglia are increasingly implicated in brain pathology, particularly neurodegenerative disease, with many genes implicated in Alzheimer's, Parkinson's, and motor neuron disease expressed in microglia. There is, therefore, a need for authentic, efficient in vitro models to study human microglial pathological mechanisms. Microglia originate from the yolk sac as MYB-independent macrophages, migrating into the developing brain to complete differentiation. Here, we recapitulate microglial ontogeny by highly efficient differentiation of embryonic MYB-independent iPSC-derived macrophages then co-culture them with iPSC-derived cortical neurons. Co-cultures retain neuronal maturity and functionality for many weeks. Co-culture microglia express key microglia-specific markers and neurodegenerative disease-relevant genes, develop highly dynamic ramifications, and are phagocytic. Upon activation they become more ameboid, releasing multiple microglia-relevant cytokines. Importantly, co-culture microglia downregulate pathogen-response pathways, upregulate homeostatic function pathways, and promote a more anti-inflammatory and pro-remodeling cytokine response than corresponding monocultures, demonstrating that co-cultures are preferable for modeling authentic microglial physiology.

Published
2017

47. A Highly Efficient Human Pluripotent Stem Cell Microglia Model Displays a Neuronal-Co-culture-Specific Expression Profile and Inflammatory Response

Author

Haenseler, Walther, primary, Sansom, Stephen N., additional, Buchrieser, Julian, additional, Newey, Sarah E., additional, Moore, Craig S., additional, Nicholls, Francesca J., additional, Chintawar, Satyan, additional, Schnell, Christian, additional, Antel, Jack P., additional, Allen, Nicholas D., additional, Cader, M. Zameel, additional, Wade-Martins, Richard, additional, James, William S., additional, and Cowley, Sally A., additional

Published
2017
Full Text
View/download PDF

49. Identification of a novel neuropathogenic theiler’s murine encephalomyelitis virus

Author

Buckwalter , Matthew R., Nga , Phan Thi, Gouilh , Meriadeg Ar., Fiette , Laurence, Bureau , Jean-François, Laird , Melissa E., Buchrieser , Julian, Ozden , Simona, Cheval , Justine, Eloit , Marc, Manuguerra , Jean-Claude, Gessain , Antoine, Brey , Paul T., Fontanet , Arnaud, Albert , Matthew L., Immunobiologie des Cellules Dendritiques, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale ( INSERM ), National Institute of Hygiene and Epidemiology ( NIHE ), Cellule d'Intervention Biologique d'Urgence ( CIBU ), Institut Pasteur [Paris], Histopathologie humaine et Modèles animaux, Département de Virologie, Epidémiologie et Physiopathologie des Virus Oncogènes, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique ( CNRS ), Génotypage des Pathogènes et Santé Publique (Plate-forme) ( PF8 ), Virologie UMR1161 ( VIRO ), Institut National de la Recherche Agronomique ( INRA ) -Ecole Nationale Vétérinaire d'Alfort-ANSES, Institut Pasteur du Laos, Réseau International des Instituts Pasteur ( RIIP ) -Institut Pasteur du Laos, Epidémiologie des Maladies Emergentes, Conservatoire National des Arts et Métiers [CNAM] ( CNAM ) -Institut Pasteur [Paris]-Pasteur-Cnam risques infectieux et émergents ( PACRI ), Institut Pasteur [Paris]-Conservatoire National des Arts et Métiers [CNAM] : EA4628-Conservatoire National des Arts et Métiers [CNAM] : EA4628, and Université Paris Descartes - Paris 5 ( UPD5 )

Subjects
[ SDV ] Life Sciences [q-bio], health care facilities, manpower, and services, Neuropathogenic, education, Theiler’s, Murine, health care economics and organizations
Abstract

International audience; absent

Published
2011

50. Identification of a novel neuropathogenic theiler’s murine encephalomyelitis virus

Author

Buckwalter, Matthew R., Nga, Phan Thi, Gouilh, Meriadeg Ar., Fiette, Laurence, Bureau, Jean-François, Laird, Melissa E., Buchrieser, Julian, Ozden, Simona, Cheval , Justine, Eloit, Marc, Manuguerra, Jean-Claude, Gessain, Antoine, Brey, Paul T., Fontanet, Arnaud, and Albert, Matthew L.

Subjects
Neuropathogenic, Theiler’s, Murine
Published
2011

Catalog

Books, media, physical & digital resources
See catalog results